Goldman Sachs Upgrades Myriad, Agilent, and Thermo Fisher; Downgrades PerkinElmer, Danaher | GenomeWeb

NEW YORK (GenomeWeb) — Goldman Sachs on Tuesday released an omnibus report of its views on specific companies and sectors of the life sciences industry. The investment bank upgraded shares of Agilent to Buy; Thermo Fisher Scientific to the Americas Conviction Buy List; and Myriad to Neutral. Goldman also downgraded PerkinElmer to Sell and Danaher and Laboratory Corporation of America to Neutral.

The bank also raised its view of the life science tools sector to Attractive, lowered its view of the labs sector to Neutral, and reiterated its Neutral view of the diagnostics market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.